Can ketamine increase the risk of nephrolithiasis?

Ketamine and Kidney Stone Risk

Yes, ketamine can worsen the chances of developing kidney stones, particularly with chronic or recurrent use, though the risk appears primarily associated with prolonged recreational abuse rather than short-term therapeutic administration.

Evidence from FDA Drug Labeling

The FDA label for ketamine explicitly warns about renal and urinary complications. In individuals with chronic ketamine use or abuse, the drug causes lower urinary tract and bladder symptoms including dysuria, increased urinary frequency, urgency, urge incontinence, and hematuria 1. Critically, diagnostic studies have documented hydronephrosis and reduced bladder capacity in chronic users 1. While the FDA label emphasizes bladder pathology (cystitis variants), the documented hydronephrosis indicates upper urinary tract involvement that could predispose to stone formation through urinary stasis.

Mechanism and Clinical Context

The urological toxicity stems from ketamine and its metabolites concentrating in urine rather than circulating in blood 2. This direct exposure damages the urothelium, causing:

• Bladder fibrosis driven by TGF-β1 signaling
• Barrier dysfunction with increased antiproliferative factor expression
• Upper tract involvement including hydronephrosis 3

Recent pharmacovigilance data specifically identifies nephrolithiasis as an adverse event associated with ketamine use 4. A 2025 comparative safety analysis found ketamine had higher odds of renal and urinary disorders compared to other antidepressant and antipsychotic drug classes 4.

Risk Stratification by Use Pattern

Recreational/Chronic Abuse Context:

• Prevalence of urological complications ranges from 44-77% for lower urinary tract symptoms and 8-30% for upper tract disease in systematic reviews of recreational users 2
• These high rates reflect frequent, high-dose, often oral administration patterns

Therapeutic Context:

• Systematic review of 27 psychiatric treatment studies found urological symptoms in 0-24% of patients 2
• In 14 randomized controlled trials, urological symptom prevalence differed little between ketamine and control arms 2
• No convincing evidence of ketamine-associated uropathy in short-term therapeutic contexts 2

Risk Factors for Stone Formation

The following increase uropathy risk during maintenance therapy 2:

• Higher ketamine doses
• More frequent dosing intervals
• Longer treatment duration
• Oral administration (versus IV/intranasal routes)

Clinical Recommendations

For patients requiring therapeutic ketamine:

1. Baseline assessment: Obtain urinalysis and consider renal ultrasound if planning long-term treatment
2. Hydration protocol: Implement high fluid intake on treatment days with frequent voiding to reduce bladder exposure to ketamine metabolites 2
3. Monitoring: Fortnightly or monthly urine testing during maintenance therapy 2
4. Route selection: Prefer IV or intranasal over oral administration when feasible
5. Dose optimization: Use minimum effective doses with extended intervals between treatments

Common pitfall: Assuming therapeutic ketamine carries the same urological risk as recreational abuse. The evidence shows dramatically different risk profiles, with therapeutic use showing minimal to no increased stone risk in controlled studies.

For patients with existing kidney stones or recurrent nephrolithiasis: Exercise heightened caution with ketamine, particularly for long-term maintenance protocols. The documented hydronephrosis risk 1 could theoretically worsen urinary stasis and stone formation risk, though this specific interaction lacks direct study evidence.